Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 25

1.

Exercise increases caudate dopamine release and ventral striatal activation in Parkinson's disease.

Sacheli MA, Neva JL, Lakhani B, Murray DK, Vafai N, Shahinfard E, English C, McCormick S, Dinelle K, Neilson N, McKenzie J, Schulzer M, McKenzie DC, Appel-Cresswell S, McKeown MJ, Boyd LA, Sossi V, Stoessl AJ.

Mov Disord. 2019 Oct 4. doi: 10.1002/mds.27865. [Epub ahead of print]

PMID:
31584222
2.

Canadian guideline for Parkinson disease.

Grimes D, Fitzpatrick M, Gordon J, Miyasaki J, Fon EA, Schlossmacher M, Suchowersky O, Rajput A, Lafontaine AL, Mestre T, Appel-Cresswell S, Kalia SK, Schoffer K, Zurowski M, Postuma RB, Udow S, Fox S, Barbeau P, Hutton B.

CMAJ. 2019 Sep 9;191(36):E989-E1004. doi: 10.1503/cmaj.181504. No abstract available.

3.

Dopamine replacement remediates risk aversion in Parkinson's disease in a value-independent manner.

Cherkasova MV, Corrow JC, Taylor A, Yeung SC, Stubbs JL, McKeown MJ, Appel-Cresswell S, Stoessl AJ, Barton JJS.

Parkinsonism Relat Disord. 2019 Sep;66:189-194. doi: 10.1016/j.parkreldis.2019.08.014. Epub 2019 Aug 26.

PMID:
31473085
4.

Altered EEG alpha and theta oscillations characterize apathy in Parkinson's disease during incentivized movement.

Zhu M, HajiHosseini A, Baumeister TR, Garg S, Appel-Cresswell S, McKeown MJ.

Neuroimage Clin. 2019;23:101922. doi: 10.1016/j.nicl.2019.101922. Epub 2019 Jul 2.

5.

Gender and funding success.

Appel-Cresswell S, Blanchet PJ, Wysocki J, Postuma RB.

Lancet. 2019 Jun 1;393(10187):2195-2196. doi: 10.1016/S0140-6736(19)31107-9. No abstract available.

PMID:
31162073
6.

Habitual exercisers versus sedentary subjects with Parkinson's Disease: Multimodal PET and fMRI study.

Sacheli MA, Murray DK, Vafai N, Cherkasova MV, Dinelle K, Shahinfard E, Neilson N, McKenzie J, Schulzer M, Appel-Cresswell S, McKeown MJ, Sossi V, Jon Stoessl A.

Mov Disord. 2018 Dec;33(12):1945-1950. doi: 10.1002/mds.27498. Epub 2018 Oct 30.

PMID:
30376184
7.

Subdural Empyema.

Gorman J, Randhawa N, Mendelsohn D, Honey CR, Heran MKS, Appel-Cresswell S.

Can J Neurol Sci. 2018 Sep;45(5):566-567. doi: 10.1017/cjn.2018.67. No abstract available.

PMID:
30234467
8.

PSEN1 p.Met233Val in a Complex Neurodegenerative Movement and Neuropsychiatric Disorder.

Appel-Cresswell S, Guella I, Lehman A, Foti D, Farrer MJ.

J Mov Disord. 2018 Jan;11(1):45-48. doi: 10.14802/jmd.17066. Epub 2018 Jan 11.

9.

Caffeine as symptomatic treatment for Parkinson disease (Café-PD): A randomized trial.

Postuma RB, Anang J, Pelletier A, Joseph L, Moscovich M, Grimes D, Furtado S, Munhoz RP, Appel-Cresswell S, Moro A, Borys A, Hobson D, Lang AE.

Neurology. 2017 Oct 24;89(17):1795-1803. doi: 10.1212/WNL.0000000000004568. Epub 2017 Sep 27.

10.

The gut microbiome in human neurological disease: A review.

Tremlett H, Bauer KC, Appel-Cresswell S, Finlay BB, Waubant E.

Ann Neurol. 2017 Mar;81(3):369-382. doi: 10.1002/ana.24901. Epub 2017 Mar 20. Review.

PMID:
28220542
11.

Gender differences in Parkinson's disease depression.

Perrin AJ, Nosova E, Co K, Book A, Iu O, Silva V, Thompson C, McKeown MJ, Stoessl AJ, Farrer MJ, Appel-Cresswell S.

Parkinsonism Relat Disord. 2017 Mar;36:93-97. doi: 10.1016/j.parkreldis.2016.12.026. Epub 2016 Dec 29.

PMID:
28089265
12.

Medical Management of Parkinson's Disease after Initiation of Deep Brain Stimulation.

Fasano A, Appel-Cresswell S, Jog M, Zurowkski M, Duff-Canning S, Cohn M, Picillo M, Honey CR, Panisset M, Munhoz RP.

Can J Neurol Sci. 2016 Sep;43(5):626-34. doi: 10.1017/cjn.2016.274. Review.

PMID:
27670207
13.

DCTN1 p.K56R in progressive supranuclear palsy.

Gustavsson EK, Trinh J, Guella I, Szu-Tu C, Khinda J, Lin CH, Wu RM, Stoessl J, Appel-Cresswell S, McKeown M, Rajput A, Rajput AH, Petersen MS, Jeon BS, Aasly JO, Farrer MJ.

Parkinsonism Relat Disord. 2016 Jul;28:56-61. doi: 10.1016/j.parkreldis.2016.04.025. Epub 2016 Apr 23.

PMID:
27132499
14.

Morphological alterations in the caudate, putamen, pallidum, and thalamus in Parkinson's disease.

Garg A, Appel-Cresswell S, Popuri K, McKeown MJ, Beg MF.

Front Neurosci. 2015 Mar 31;9:101. doi: 10.3389/fnins.2015.00101. eCollection 2015.

15.

Parkinsonism in GTP cyclohydrolase 1 mutation carriers.

Guella I, Sherman HE, Appel-Cresswell S, Rajput A, Rajput AH, Farrer MJ.

Brain. 2015 May;138(Pt 5):e349. doi: 10.1093/brain/awu341. Epub 2014 Dec 13. No abstract available.

16.

DNAJC13 genetic variants in parkinsonism.

Gustavsson EK, Trinh J, Guella I, Vilariño-Güell C, Appel-Cresswell S, Stoessl AJ, Tsui JK, McKeown M, Rajput A, Rajput AH, Aasly JO, Farrer MJ.

Mov Disord. 2015 Feb;30(2):273-8. doi: 10.1002/mds.26064. Epub 2014 Nov 12.

PMID:
25393719
17.

Clinical, positron emission tomography, and pathological studies of DNAJC13 p.N855S Parkinsonism.

Appel-Cresswell S, Rajput AH, Sossi V, Thompson C, Silva V, McKenzie J, Dinelle K, McCormick SE, Vilariño-Güell C, Stoessl AJ, Dickson DW, Robinson CA, Farrer MJ, Rajput A.

Mov Disord. 2014 Nov;29(13):1684-7. doi: 10.1002/mds.26019. Epub 2014 Sep 3.

PMID:
25186792
18.

In vivo dopaminergic and serotonergic dysfunction in DCTN1 gene mutation carriers.

Felicio AC, Dinelle K, Agarwal PA, McKenzie J, Heffernan N, Road JD, Appel-Cresswell S, Wszolek ZK, Farrer MJ, Schulzer M, Sossi V, Stoessl AJ.

Mov Disord. 2014 Aug;29(9):1197-201. doi: 10.1002/mds.25893. Epub 2014 May 5.

19.

A genetically informed, group FMRI connectivity modeling approach: application to schizophrenia.

Liu A, Chen X, Wang ZJ, Xu Q, Appel-Cresswell S, McKeown MJ.

IEEE Trans Biomed Eng. 2014 Mar;61(3):946-56. doi: 10.1109/TBME.2013.2294151.

PMID:
24557696
20.

DNAJC13 mutations in Parkinson disease.

Vilariño-Güell C, Rajput A, Milnerwood AJ, Shah B, Szu-Tu C, Trinh J, Yu I, Encarnacion M, Munsie LN, Tapia L, Gustavsson EK, Chou P, Tatarnikov I, Evans DM, Pishotta FT, Volta M, Beccano-Kelly D, Thompson C, Lin MK, Sherman HE, Han HJ, Guenther BL, Wasserman WW, Bernard V, Ross CJ, Appel-Cresswell S, Stoessl AJ, Robinson CA, Dickson DW, Ross OA, Wszolek ZK, Aasly JO, Wu RM, Hentati F, Gibson RA, McPherson PS, Girard M, Rajput M, Rajput AH, Farrer MJ.

Hum Mol Genet. 2014 Apr 1;23(7):1794-801. doi: 10.1093/hmg/ddt570. Epub 2013 Nov 11.

21.

Decisions under risk in Parkinson's disease: preserved evaluation of probability and magnitude.

Sharp ME, Viswanathan J, McKeown MJ, Appel-Cresswell S, Stoessl AJ, Barton JJ.

Neuropsychologia. 2013 Nov;51(13):2679-89. doi: 10.1016/j.neuropsychologia.2013.08.008. Epub 2013 Aug 15.

PMID:
23954375
22.

Alpha-synuclein p.H50Q, a novel pathogenic mutation for Parkinson's disease.

Appel-Cresswell S, Vilarino-Guell C, Encarnacion M, Sherman H, Yu I, Shah B, Weir D, Thompson C, Szu-Tu C, Trinh J, Aasly JO, Rajput A, Rajput AH, Jon Stoessl A, Farrer MJ.

Mov Disord. 2013 Jun;28(6):811-3. doi: 10.1002/mds.25421. Epub 2013 Mar 1.

PMID:
23457019
23.

Novel spatial analysis method for PET images using 3D moment invariants: applications to Parkinson's disease.

Gonzalez ME, Dinelle K, Vafai N, Heffernan N, McKenzie J, Appel-Cresswell S, McKeown MJ, Stoessl AJ, Sossi V.

Neuroimage. 2013 Mar;68:11-21. doi: 10.1016/j.neuroimage.2012.11.055. Epub 2012 Dec 11.

PMID:
23246861
24.

Functional neuroimaging in Parkinson's disease.

de la Fuente-Fernández R, Appel-Cresswell S, Doudet DJ, Sossi V.

Expert Opin Med Diagn. 2011 Mar;5(2):109-20. doi: 10.1517/17530059.2011.554820. Epub 2011 Feb 1.

PMID:
23480585
25.

Imaging of compensatory mechanisms in Parkinson's disease.

Appel-Cresswell S, de la Fuente-Fernandez R, Galley S, McKeown MJ.

Curr Opin Neurol. 2010 Aug;23(4):407-12. doi: 10.1097/WCO.0b013e32833b6019. Review.

PMID:
20610991

Supplemental Content

Loading ...
Support Center